Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Foghorn Therapeutics Inc. | Chief Financial Officer | Common Stock | 53.8K | $444K | $8.25 | Jan 16, 2024 | Direct |
Foghorn Therapeutics Inc. | Chief Financial Officer | Stock Option (right to buy) | 90K | $275K | $3.06 | Jan 16, 2024 | Direct |
Prime Medicine, Inc. | Chief Financial Officer | Stock Option (right to buy) | 100K | May 17, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
PRME | Prime Medicine, Inc. | May 17, 2024 | 1 | $0 | 4 | May 21, 2024 | Chief Financial Officer |
PRME | Prime Medicine, Inc. | Jan 17, 2024 | 1 | $0 | 4 | Jan 19, 2024 | Chief Financial Officer |
PRME | Prime Medicine, Inc. | Jan 17, 2024 | 0 | $0 | 3 | Jan 19, 2024 | Chief Financial Officer |
FHTX | Foghorn Therapeutics Inc. | Jan 16, 2024 | 0 | $0 | 4 | Jan 17, 2024 | Chief Financial Officer |
FHTX | Foghorn Therapeutics Inc. | Jan 26, 2023 | 1 | $0 | 4 | Jan 30, 2023 | Chief Financial Officer |
FHTX | Foghorn Therapeutics Inc. | Jan 26, 2022 | 1 | $0 | 4 | Jan 28, 2022 | Chief Financial Officer |
FHTX | Foghorn Therapeutics Inc. | Aug 9, 2021 | 2 | $100K | 4 | Aug 11, 2021 | Chief Financial Officer |